BioXcel Therapeutics Inc (NASDAQ:BTAI)
| 12.25 Delayed Data As of May 27 |  +0.71 / +6.15%Today’s Change | 9.08 Today|||52-Week Range 39.00 | -39.74% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $342.5M |
Company Description
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
Contact Information
BioXcel Therapeutics, Inc. 555 Long Wharf Drive New Haven Connecticut 06511 |
Employees
Shareholders
| Mutual fund holders | 34.38% |
| Individual stakeholders | 32.21% |
| Other institutional | 17.32% |
Top Executives
| Vimal D. Mehta | President, Chief Executive Officer & Director |
| Richard I. Steinhart | Chief Financial Officer & Vice President |
| Frank D. Yocca | Chief Scientific Officer & Senior Vice President |
| Vincent J. O'Neill | Chief Medical Officer & Senior Vice President |
| Javier Rodriguez | Secretary, Chief Legal Officer & Senior VP |
